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Introduction
Hyperthyroidism is associated with an increased 
morbidity and mortality from cardiovascular disease.1 
Heart failure occurs in between 6-16% of hyperthyroid 
patients.2-4 Thyrotoxicosis is commonly associated with 
exacerbation of underlying coronary heart disease, 
with atrial fibrillation and systolic dysfunction.5 It is 
less well appreciated that hyperthyroidism is also 
associated with pulmonary arterial hypertension (PAH) 
and right heart failure.
We describe three patients who presented with 
thyrotoxicosis and features of PAH in whom other causes 
of PAH had been excluded. We also demonstrate 
reversibility of the pulmonary hypertension upon 
restoration of the euthyroid state. The possible 
aetiology and clinical significance of this association 
will be discussed.
Case 1
A 55-year-old female presented with evidence of 
severe Graves’ thyrotoxicosis, complicated by proximal 
muscle weakness and mild thyroid eye disease. She had 
a past history of left breast carcinoma, for which she 
simultaneously underwent a left radical mastectomy 
and radiotherapy. She was also a smoker, known to 
have mild chronic obstructive lung disease (COPD), 
and was on treatment for systemic hypertension. 
Further clinical examination revealed marked bipedal 
oedema, as well as an elevated jugular venous pressure 
(JVP) (15 cm) and loud pulmonary component of the 
second heart sound. Scattered bilateral wheezing 
was present, with a central trachea. The mastectomy 
scar was noted on the left. Chest radiography showed 
hyperinflation and evidence of the previous surgery on 
the left (Figure 1). 
Further tests revealed an FT4 of 65.7 pmol/l (10.3-21.9), 
FT3 > 30.8 pmol/l (3.1-6.8) and thyroid-stimulating 
hormone (TSH) < 0.01mIU/l (0.35-4.5). She had a TSH 
receptor antibody titre of > 40 (0-1.75) and a technetium 
thyroid uptake scan that is typical of Graves’ disease. 
An echocardiography showed an elevated pulmonary 
arterial systolic pressure of 64 mmHg (normal values on 
echocardiography < 30 mmHg), no valvular pathology, 
a mildly dilated left ventricle with mild impairment of 
systolic function (left ventricular ejection fraction 45%), 
and an element of diastolic dysfunction. 
Investigations were carried out to establish the cause of 
the elevated pulmonary pressure. A normal ventilation/
perfusion (V/Q) scan excluded pulmonary embolism. 
Her spirometrical parameters were within normal limits 
[forced expiratory volume in one second (FEV1)/forced 
vital capacity (FVC) 71.13 and FEV1 83.8%]. However, 
TLCOc (diffusion capacity) was decreased at 58% 
(normal > 70%). In view of this, as well as the previous 
history of radiation therapy, we proceeded to carry out 
a high-resolution computed tomography (CT) scan of 
her chest. This showed no evidence of interstitial lung 
disease.
Initially, she was started on carbimazole, and then 
treated with radioactive iodine (RAI). Subsequently, 
the clinical signs of cor pulmonale resolved, and an 
echocardiography that was performed when she was 
euthyroid demonstrated that the pulmonary pressure 
had normalised to 25 mmHg. 
Case 2
A 44-year-old male, who was previously well, presented 
with severe thyrotoxicosis and a five-month history 
of progressive dyspnoea, orthopnoea, bilateral leg 
swelling, loss of weight and generalised weakness. 
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Abstract
Thyrotoxicosis is listed as a cause of pulmonary arterial hypertension (PAH). The aetiopathogenesis remains largely 
uncertain, but an autoimmune mechanism has been postulated, among others. In this setting, other causes of PAH 
need to be actively sought and excluded prior to attributing it to the thyrotoxicosis. The importance of recognising 
this condition is that it is usually reversible with restoration of a euthyroid state. We describe three patients who 
presented with thyrotoxicosis and features of PAH in whom other causes were excluded with various investigations. 
We also demonstrated reversibility of the pulmonary hypertension upon restoration of a normal thyroid state.
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He had atrial fibrillation and clinical evidence of right 
ventricular enlargement and pulmonary hypertension 
(parasternal heave and loud second heart sound), 
and severe right heart failure (gross bipedal oedema, 
hepatic congestion and markedly elevated JVP). He 
also had evidence of a right-sided pleural effusion. No 
thyromegaly or evidence of thyroid eye disease was 
present.
Thyroid function tests showed an FT4 of > 155 pmol/l, 
FT3 of > 30.8 pmol/l and TSH < 0.01 mIU/l. A technetium 
thyroid scan was consistent with Graves’ disease, 
and revealed an increased uptake of 16% (normal: 
0.75-4%). Chest radiography (Figure 2) demonstrated 
an enlarged right ventricle, as well as a right-sided 
pleural effusion. Analysis of the fluid showed that it was 
a transudate. 
Echocardiography demonstrated a severely dilated 
right atrium and ventricle, moderate tricuspid 
regurgitation and good left ventricular function. 
Pulmonary arterial pressure was 50 mmHg.
Figure 1: The posteroanterior and lateral views of the chest radiograph of patient number 1 showed hyperinflation, left ventricular 
hypertrophy, a small right-sided pleural effusion and surgical clips from a left mastectomy
Figure 2: The posteroanterior and lateral views of the chest radiograph of patient number two revealed right ventricular 
hypertrophy with a moderate right-sided pleural effusion 
Case Study: Pulmonary hypertension and thyrotoxicosis
103 2012 Volume 17 No 2JEMDSA
In view of the marked cor pulmonale, a pulmonary 
CT-angiography was performed, and this excluded any 
thromboembolic disease. However, in the light of his 
atrial fibrillation, a decision was made to anticoagulate 
him with low-molecular-weight heparin and warfarin. 
The patient was treated with RAI, and subsequently 
became hypothyroid. His cardiac status improved 
markedly and the pleural effusion cleared, although he 
did remain in atrial fibrillation. Currently, he is on thyroid 
replacement therapy and warfarin, and anti-failure 
medication has been significantly decreased. 
A subsequent echocardiography, at a time when he 
was euthyroid, demonstrated improvement in his right 
ventricular dilatation and function. He still had biatrial 
enlargement. This is most likely to be due to remodelling. 
The pulmonary arterial pressure had normalised to 
30 mmHg.
Case 3
A 72-year-old female presented to us with clinical 
features of thyrotoxicosis. Medical therapy with 
carbimazole had apparently been initiated six months 
before. She had no features of heart failure, but had 
evidence of pulmonary hypertension with a right 
ventricular heave, and a loud pulmonary component 
of the second heart sound. The rest of the clinical 
examination was normal. Previous medical history was 
unremarkable, with no history of smoking. 
Thyroid function tests revealed an FT4 of 43.0 pmol/l 
and FT3 of 8.5 pmol/l, with a TSH < 0.01 mIU/l. The TSH 
receptor antibody titre was markedly increased at 
23.44 (0-1.75). Chest radiography was normal. An 
echocardiography showed a normal left ventricular 
ejection fraction of 67%, slight diastolic dysfunction, 
and raised pulmonary arterial pressure of 54 mmHg.
The patient was treated with RAI, and remained 
euthyroid thereafter. A subsequent echocardiography 
showed that pulmonary artery pressure had nearly 
normalised to 37 mmHg (Table I).
Discussion
Although hyperthyroidism is classically associated with 
left ventricular dysfunction and heart failure, awareness 
that this disease may also at times predominantly, if not 
exclusively, involve the right heart has increased over 
the past few years.6-8 However, the true prevalence 
and clinical significance of this complication remain 
unclear. Isolated case reports, often involving patients 
presenting with acute cor pulmonale, suggest that the 
association of thyrotoxicosis and PAH is rare. However, 
a limited number of observational studies have 
documented the prevalence of PAH in hyperthyroidism 
to range from 41-65%. The largest observational 
study, by Marvisi et al, evaluated 114 patients with 
hyperthyroidism (47 with Graves’ disease and 67 with 
toxic nodular goitre), and found mild PAH in 43%, and 
no case of PAH in the control group.9 More recently, 
Siu et al evaluated 75 patients with hyperthyroidism 
and normal left ventricular systolic function, and 
found that up to 47% had (asymptomatic) pulmonary 
hypertension, either due to PAH with increased 
cardiac output or pulmonary venous hypertension with 
elevated left ventricular filling pressure.10
Usually, these observational studies have documented 
only mild degrees of PAH in patients presenting with 
thyrotoxicosis primarily. Conversely, a retrospective 
study found a significantly higher prevalence of 
thyroid disease in 356 patients presenting with 
severe pulmonary hypertension, compared with an 
appropriately matched control group [odds ratio 
(OR) 2.53, 95% confidence interval (CI) 1.55-4.08, 
p-value < 0.001).11 Interestingly, most patients had mild 
thyroid disease and were often not hyperthyroid, but 
hypothyroid.
Most reports have focused on middle-aged females, 
although the association between hyperthyroidism 
and PAH has also been reported in men.12 Our second 
patient, who presented with the most severe degree 
of right heart failure and hyperthyroidism, was a male.
The aetiology of the pulmonary hypertension that 
has been observed in subjects with hyperthyroidism 
remains unclear, but various mechanisms have been 
proposed. These include endothelial injury due to 
the high cardiac output that often accompanies the 
hyperthyroid state.6,13 Given the fact that PAH may 
also develop in the absence of an increased cardiac 
output, this proposed mechanism clearly does not 
explain all cases. Hyperthyroidism-induced vasospasm 
has been suggested by some,14 although little objective 
evidence exists to support this theory. Likewise, it has 
been hypothesised that an increased metabolism of 
intrinsic pulmonary vasodilators may underlie the PAH, 
but scant data support this concept.13 Hyperthyroidism 
Table I: Thyroid functions and pulmonary artery pressures 
Characteristics Case 1 Case 2 Case 3
Age (years) 55 44 72
Gender Female Male Female
FT4
(10.3-21.9 pmol/l)
65.7 > 155 43
TSH
(0.35-4.5 mIU/l)
< 0.01 < 0.01 < 0.01
TSH R Ab
(0.00-1.75 IU/l)
> 40 - 23.44l
Microsomal ab
( 0-9 IU/ml) - 1:1 600 -
PAP before
( < 30 mmHg) 64 50 54
PAP after
( < 30 mmHg) 25 30 37
microsomal ab: microsomal thyroperoxidase antibody, PAP: pulmonary 
arterial pressure, TSH: thyroid-stimulating hormone, TSH R ab: thyroid-stimulating 
hormone receptor antibody, microsomal or thyroperoxidase
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is commonly associated with hypercoagulability and 
an increased prevalence of deep vein thrombosis,15 
as well as a two- to threefold increased prevalence 
of pulmonary embolism, even after correcting for 
confounders.16 Thus, pulmonary embolism may 
account for a definite number of patients presenting 
with PAH, and always needs to be excluded. However, 
as was evident in our own patients, PAH has been 
adequately documented in hyperthyroid patients in 
the absence of any pulmonary embolism. Therefore, it 
cannot account for the vast majority of cases.
An attractive hypothesis to explain the association 
between PAH and thyroid disease relates to 
autoimmunity. In a series of 40 patients with apparent 
primary pulmonary hypertension, Yanai-Landau et 
al found an eightfold increase in the incidence of 
anti-thyroglobulin antibodies over that of the general 
population.17 Therefore, the question arises as to 
whether immune activation in hyperthyroidism may 
account for endothelial damage or dysfunction, 
causing pulmonary hypertension. In another study 
of 63 consecutive patients with pulmonary arterial 
hypertension, it was found that half the patients had 
evidence of autoimmune thyroid disease or a family 
history thereof.18 Most of these studies have assessed 
anti-thyroglobulin or microsomal anti-thyroperoxidase 
antibodies, and we are not aware of studies which 
measured TSH receptor antibodies. Some apparent 
cases of primary or idiopathic PAH in children have, in 
retrospect, been shown to precede, by five years or 
more, the development of autoimmune polyglandular 
endocrine syndromes comprising type 1 diabetes and 
hyperthyroidism.19 The autoimmune thyroid diseases, 
such as Graves and Hashimoto’s thyroiditis, have been 
shown to be more frequently associated with PAH, than 
multinodular goiter has, for example, lending credence 
to a possible autoimmune basis for this association. In 
fact, Sahin et al found euthyroid Hashimoto’s patients 
to have higher pulmonary arterial pressures, than 
controls (31.6 ± 5 vs. 25.6 ± 4.5 mmHg, p-value = 0.005).20
Reversibility of PAH upon treatment of the underlying 
thyrotoxicosis has been demonstrated consistently 
in the vast majority of cases.10,21 In one study, it was 
demonstrated that a more rapid drop in pulmonary 
arterial pressures could be achieved with anti-
thyroid drugs, compared with partial thyroidectomy, 
suggesting a possible role for the anti-thyroid drugs 
per se.9 However, in our patients, normalisation of the 
pulmonary pressures was achieved in all three cases 
with RAI.
Conclusion
Thyroid disease, in particular Graves’ disease, should 
be recognised as a cause of PAH and cor pulmonale. 
The exact prevalence, pathophysiology, and clinical 
significance of this association is yet to be determined. 
In this setting, it is imperative to exclude other causes 
of pulmonary hypertension, especially pulmonary 
embolism, which is known to occur more frequently 
in hyperthyroidism. The importance in recognising the 
association between PAH and hyperthyroidism lies in 
the fact that reversibility of the pulmonary hypertension 
is usually achieved upon restoration of the euthyroid 
state. Therefore, all patients presenting with apparent 
primary pulmonary hypertension should be screened 
for thyroid disease. Given the fact that, especially in 
children, the PAH may precede the development of 
the thyroid disorder by many years, it may be prudent 
to repeat thyroid function tests after a period of time in 
these individuals. 
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